A pharmacogeneticist's look at drug effects and the drug development process: an overview

被引:4
作者
Kalow, W [1 ]
机构
[1] Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada
关键词
common diseases; drug development; drug metabolism; drugs; drug targets; genes; human races; personalised medicine; pharmacogenetics;
D O I
10.1517/14656566.6.8.1299
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This paper describes the functional roles of the closely related pharmacogenetic and pharmacogenomic sciences in medicine. Firstly, they provide means for a better understanding of the function of drugs, and particularly of the differences of drug action between individuals and also between racially categorised populations. Secondly, they are repeatedly used during the long process of new drug development, the developer needs several patient contacts. The development starts with target identification and ends with an official permission for medical use of a drug.
引用
收藏
页码:1299 / 1303
页数:5
相关论文
共 34 条
  • [1] [Anonymous], PHARMACOGENOMICS SEA
  • [2] Applications of pharmacogenetics to drug development: The Glaxo Wellcome experience
    Arledge, T
    Freeman, A
    Arbuckle, J
    Mosteller, M
    Manasco, P
    [J]. DRUG METABOLISM REVIEWS, 2000, 32 (3-4) : 387 - 394
  • [3] Target discovery and validation in the post-genomic era
    Butcher, SP
    [J]. NEUROCHEMICAL RESEARCH, 2003, 28 (02) : 367 - 371
  • [4] GOOD CLINICAL PRACTICES IN PHASE-I STUDIES
    DECOUSUS, H
    PERPOINT, B
    MISMETTI, P
    OLLAGNIER, M
    QUENEAU, P
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1990, 4 : S163 - S165
  • [5] EVANS DAP, 1964, J LAB CLIN MED, V63, P394
  • [6] Clinical trials in the genomic era: Effects of protective genotypes on sample size and duration of trial
    Fijal, BA
    Hall, JM
    Witte, JS
    [J]. CONTROLLED CLINICAL TRIALS, 2000, 21 (01): : 7 - 20
  • [7] Grant D M, 1999, Can J Clin Pharmacol, V6, P131
  • [8] Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor
    Hjerde, E
    Dahl, SG
    Sylte, I
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2005, 40 (02) : 185 - 194
  • [9] Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
    Ingelman-Sundberg, M
    [J]. PHARMACOGENOMICS JOURNAL, 2005, 5 (01) : 6 - 13
  • [10] INNOCENTI F, 2002, PHARMACOGENOMICS SEA, P283